Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Support
This activity is funded by PER®.
Current Knowledge and New Directions in Cholangiocarcinoma
Release Date: May 1, 2020
Expiration Date: May 1, 2021
This continuing medical education (CME) activity is designed to inform health care providers who care for patients with cholangiocarcinoma (CCA) of the opportunities and challenges in the management of patients with CCA using novel targeted therapies. The in-depth program will cover best practices for the identification of patients with CCA who are most likely to benefit from these agents, the specific mechanistic characteristics of these agents, and techniques for managing adverse events appropriately. In addition, available clinical trial data will be examined and contextualized in the standard of care for patients with CCA.
Acknowledgement of Support
This activity is funded by PER®.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate.
Upon successful completion of this educational activity, you should be better prepared to:
- Outline methods that allow for optimized characterization of tumor biology among patients with cholangiocarcinoma
- Explain the study design, rationale, and results of recent clinical trials evaluating novel strategies for the treatment of cholangiocarcinoma
- Consider recent evidence in the context of evolving treatment paradigms in the field of cholangiocarcinoma
This activity was written by PER® editorial staff under faculty guidance and review. The Q&A portion of the activity was transcribed from a recorded interview with the faculty and edited by faculty and PER® editorial staff for clarity.
Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Department of Gastrointestinal Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Disclosures: Consultant: Bayer, BeiGene, Incyte Medical Affairs, Merck, Novartis, Pieris Pharmaceuticals, Inc, QED Therapeutics Inc, Rafael Pharmaceuticals, Seattle Genetics.
The staff Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.